

Anti-TNFRSF13C/BAFFR/CD268 Antibody (Ianalumab)

Introduction

Ianalumab (VAY-736) is a humanized, decarboxylated antibody targeting BAFF-R. Ianalumab blocks the interaction between BAFF and BAFF-R, antagonizing BAFF-mediated protection from apoptosis. Ianalumab has antibody-dependent cellular cytotoxicity (ADCC) that is dependent on immunoreceptor tyrosine-based activation motifs (ITAMs)-mediated activation of effector cells.

Product parameters

Alternative Names	VAY-736, NOV-5
Target Accession	Q96RJ3
Target	TNFRSF13C / BAFFR / CD268
CAS number	1929549-92-7
Molecular Weight	146.44 kDa
Host	CHO
Reactivity	Human
Conjugation	Unconjugated
Form	Liquid
Concentration	See label
Buffer System	100 mM Pro 20 mM Arg pH 5.0. No preservative!
Clonality	Monoclonal
Purification	Protein A
Isotype	IgG1
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	Immobilized human GPA33 / A33, Fc Tag at 2 ug/mL can bind Ianalumab, EC50=0.008489 ug/mL.
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 µM filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

Note

1. This product is for scientific research use only.



APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

